Hosted on MSN1mon
Ipsen and Biomunex enter agreement for cancer therapy
Biomunex CEO, founder and president Dr Pierre-Emmanuel Gerard stated: “This agreement with such an innovative oncology company as Ipsen is proof of the relevance of the MAIT-engager approach of ...
pharmaphorum4d
After FDA setback, Ipsen gets first OK for rare disease drug palovarotene
"FOP is a progressive and debilitating condition which has such a profound impact on patients, and their families," said Dr Howard Mayer, Ipsen's head of R&D. "Until today, there was no approved ...